HK Stock Market Move | BIOHEART-B(02185) rose more than 4%. IBERIS RDN system has completed market access and first commercial surgery in Switzerland.

BIOHEART-B (02185) rose more than 4%, as of the time of reporting, it had risen by 4.57%, to HK$7.78, with a turnover of HK$4.5541 million. On the news front, on October 23, BIOHEART-B announced that its subsidiary Shanghai Antong Medical Technology Co., Ltd. (Antong) has successfully completed market access and the first commercial operation of the Iberis Multi-polar Renal Artery Radiofrequency Ablation System (Iberis RDN System) in Switzerland. The surgery was performed at the University Hospital Basel. There were no reports of complications or adverse events. This case was supported by Baisheng International Group Limited (Baisheng) and Antong. Antong has entered into a strategic partnership with Baisheng for the commercialization of the Iberis RDN System, with cooperation covering multiple regions including but not limited to EU countries, the Asia-Pacific region, and the Latin American (LATAM) region. As of the date of this announcement, the Iberis RDN System is the only renal denervation (RDN) product globally approved for use through both transradial artery (TRA) and transfemoral artery (TFA) approaches. TRA makes RDN safer, more effective, and more affordable. The company's ultimate goal is to provide outpatient RDN surgery for patients worldwide. Antong obtained the CE mark for the Iberis RDN System in Europe in 2016.